<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Using immunohistochemical methods, we evaluated zeta-associated protein (ZAP)-70 expression in 341 cases of non-Hodgkin and Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In B-cell NHL, ZAP-70 was positive in five of six (83%) precursor B-lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 11 of 37 (30%) <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>/small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="C1302547" disease_type="Neoplastic Process" abbrv="">CLL/SLL</z:e>), five of 39 (13%) mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, one of 12 (8%) Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and one of 12 (8%) nodal marginal zone B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In 22 cases of <z:e sem="disease" ids="C1302547" disease_type="Neoplastic Process" abbrv="">CLL/SLL</z:e>, seven of nine (78%) with unmutated IgVH genes expressed ZAP-70, compared with one of 13 (8%) with mutated IgVH genes (P=0.0015 Fisher's exact test) </plain></SENT>
<SENT sid="3" pm="."><plain>ZAP-70 expression was not detected in diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n=26), extranodal marginal zone B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> of mucosa-associated lymphoid tissue (n=24), follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n=21), plasma cell <z:mp ids='MP_0009440'>myeloma</z:mp>/<z:hpo ids='HP_0011857'>plasmacytoma</z:hpo> (n=10), lymphoplasmacytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n=10), or splenic marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n=6) </plain></SENT>
<SENT sid="4" pm="."><plain>In T/NK-cell NHL, ZAP-70 was positive in <z:hpo ids='HP_0000001'>all</z:hpo> extranodal natural killer (NK) / T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, nasal-type (n=6) and <z:hpo ids='HP_0002242'>enteropathy</z:hpo>-type T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n=4), four of five (80%) subcutaneous <z:mp ids='MP_0011164'>panniculitis</z:mp>-like T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, six of eight (75%) <z:e sem="disease" ids="C0026948" disease_type="Neoplastic Process" abbrv="">mycosis fungoides</z:e>, three of five (60%) precursor T-lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 10 of 17 (59%) peripheral T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, two of four (50%) blastic NK-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, one of three (33%) T-cell prolymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, 13 of 52 (25%) anaplastic large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and one of six (17%) angioimmunoblastic T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Seven of 12 (58%) cutaneous CD30-positive <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> were also ZAP-70-positive </plain></SENT>
<SENT sid="6" pm="."><plain>In Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, ZAP-70 was negative in neoplastic cells in <z:hpo ids='HP_0000001'>all</z:hpo> cases tested </plain></SENT>
<SENT sid="7" pm="."><plain>ZAP-70 staining in B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and reactive T cells was predominantly nuclear with variable cytoplasmic staining </plain></SENT>
<SENT sid="8" pm="."><plain>By contrast, ZAP-70 staining in T/NK-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> was <z:hpo ids='HP_0001425'>heterogeneous</z:hpo>, and a shift from predominantly nuclear to predominantly cytoplasmic staining was observed, particularly in those <z:hpo ids='HP_0002664'>neoplasms</z:hpo> with high-grade <z:mp ids='MP_0000002'>morphology</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>In summary, ZAP-70 is expressed by many <z:hpo ids='HP_0002665'>lymphoma</z:hpo> types, correlates with immunoglobulin heavy-chain variable region gene mutational status in <z:e sem="disease" ids="C1302547" disease_type="Neoplastic Process" abbrv="">CLL/SLL</z:e>, and can be detected reliably using immunohistochemical methods </plain></SENT>
</text></document>